Key Takeaways
- •SS-31, elamipretide, Bendavia and MTP-131 are one molecule. The sequence is D-Arg-Dmt-Lys-Phe-NH2, the free base is C32H49N9O5 at 639.8 g/mol, and the CAS number is 736992-21-5 (PubChem CID 11764719).
- •The mechanism moved from "antioxidant" to "cardiolipin binder" over a decade. The 2004 paper credited the Dmt residue with scavenging; later work showed cardiolipin binding, protection of cytochrome c's electron-carrier role and, in 2020, changes to membrane surface charge. The FDA now classes it as a "mitochondrial cardiolipin binder".
- •The randomized evidence is mostly negative on primary endpoints. TAZPOWER part 1, MMPOWER-3, EMBRACE STEMI, PROGRESS-HF and ReCLAIM-2 each missed their primary endpoints; the positive signals come from open-label extensions, small early trials, subgroups and secondary measures.
- •The 2025 approval overruled the FDA's own review team. The clinical and statistical reviewers recommended a second Complete Response; the office director, as signatory authority, granted accelerated approval on knee extensor strength from a 12-patient trial and its open-label extension, with a 72-week confirmatory trial now recruiting.
- •Mass spectrometry alone cannot confirm SS-31. The opioid peptide [Dmt1]DALDA has the identical formula and exact mass, and an L-Arg diastereomer is indistinguishable by mass; sequence-specific fragments, retention against a reference standard and chiral methods do that work.
- •The salt form changes how much peptide a milligram holds. The approved drug substance is a trihydrochloride (749.2 g/mol); acetate and trifluoroacetate salts carry less peptide per milligram, which is why net peptide content is reported separately from purity.
Summary
SS-31 (elamipretide) is a four-residue, triply charged peptide that concentrates at the inner mitochondrial membrane and interacts with cardiolipin, and that mechanism is better established than its clinical effect. Across the published placebo-controlled trials, most primary endpoints were not met, and the 2025 FDA accelerated approval for Barth syndrome rests on knee extensor strength measured in an open-label extension, a judgement the agency's own reviewers disputed. No elamipretide product is listed in Health Canada's Drug Product Database. For a laboratory, the practical problem is identity: SS-31 shares its exact mass with a known opioid peptide and with its own L-Arg diastereomer, so a certificate is only as informative as the methods behind it. A research vial is a reagent characterized for purity, identity and peptide content, and trial results describe a different, approved or investigational drug product.
SS-31 is the research name of elamipretide, a synthetic tetrapeptide with the sequence D-Arg-Dmt-Lys-Phe-NH2, where Dmt is 2',6'-dimethyl-L-tyrosine. It is the same molecule that was developed as Bendavia and MTP-131, it carries CAS number 736992-21-5, and PubChem gives its free base as C32H49N9O5 with a molecular weight of 639.8 g/mol. In the primary literature it partitions into the inner mitochondrial membrane and binds cardiolipin, the phospholipid that shapes the cristae. On 19 September 2025 the US Food and Drug Administration granted an elamipretide product accelerated approval for Barth syndrome, on a single intermediate endpoint, knee extensor strength, with a confirmatory trial required. Health Canada's Drug Product Database lists no elamipretide product.
This article sets out what is actually known: the chemistry, how the mechanism was worked out and revised, what each major trial measured and found (including the ones that missed), how the 2025 decision was reached inside the FDA, and why SS-31 is one of the harder small peptides to verify, because a correct mass does not prove a correct molecule. It is written for laboratory and in-vitro research procurement; it contains no dosing, administration or human-use guidance, and none should be inferred.
What SS-31 Is: Identity and Chemistry
SS-31 belongs to the Szeto-Schiller peptides, a family of aromatic-cationic tetrapeptides named for Hazel Szeto of Weill Cornell Medical College (PMID 21638136) and Peter Schiller, whose joint papers on this chemistry include work from the Laboratory of Chemical Biology and Peptide Research at the Clinical Research Institute of Montreal (PMID 14612191). The family grew out of opioid peptide work: the related compound [Dmt1]DALDA (H-Dmt-D-Arg-Phe-Lys-NH2) is a potent and selective mu opioid receptor agonist (PMID 14534366). SS-31 rearranges the same four residues so that D-Arg comes first and Dmt second, and the literature on SS-31 treats it as a mitochondria-targeted compound rather than an opioid ligand.
| Property | Value | Source |
|---|---|---|
| Sequence | D-Arg-Dmt-Lys-Phe-NH2 (Dmt = 2',6'-dimethyl-L-tyrosine) | PubChem CID 11764719 |
| Names | SS-31, elamipretide (INN/USAN), Bendavia, MTP-131, Szeto-Schiller peptide | PubChem synonyms |
| CAS number | 736992-21-5 (free base) | PubChem |
| Molecular formula | C32H49N9O5 (free base) | PubChem |
| Molecular weight | 639.8 g/mol (free base) | PubChem |
| Monoisotopic mass | 639.3857 Da | PubChem |
| Stereochemistry | Arg is D (2R); Dmt, Lys and Phe are L (2S) | PubChem IUPAC name |
| C-terminus | Amide (phenylalaninamide) | PubChem |
| Approved salt form | Trihydrochloride, C32H49N9O5 · 3HCl, 749.2 g/mol | FDA label, section 11 |
| UNII | 87GWG91S09 | PubChem synonyms |
Three features matter for anyone handling or testing it:
- Two non-coded elements. The N-terminal arginine is the D-enantiomer and the second residue is Dmt, a tyrosine carrying two methyl groups on the aromatic ring. Neither is among the 20 genetically coded amino acids, so both are checkable points of identity.
- Three positive charges. The N-terminal amine, the arginine guanidinium and the lysine side chain are all basic, and the amidated C-terminus removes the only carboxylic acid. A 2022 review describes a net charge of 3+ at physiological pH (PMID 35707274), which is consistent with the approved drug substance being a 1:3 hydrochloride.
- Alternating aromatic and cationic residues. Szeto's 2006 review identifies this aromatic-cationic arrangement as the structural motif of the SS peptides, which are cell-permeable and targeted to the inner mitochondrial membrane (PMID 16796378).
How SS-31 Interacts With Mitochondria
The mechanism is best read as a story that changed as better tools arrived, and many pages still describe the 2004 version.
2004: an "antioxidant" that concentrates in mitochondria. Zhao and colleagues reported that SS peptides are cell-permeable and concentrate about 1,000-fold in the inner mitochondrial membrane, reduce reactive oxygen species and cell death in neuronal N2A cells with EC50 values in the nanomolar range, and inhibit mitochondrial permeability transition and swelling in isolated mitochondria. Analogs lacking Dmt did not inhibit mitochondrial ROS or swelling, which pointed to Dmt as the active scavenging group (PMID 15178689). A 2022 review cites a figure of about 5,000-fold in isolated mitochondria (PMID 35707274); the enrichment number depends on the preparation and should be quoted with its source.
2013: cardiolipin binding. Using a polarity-sensitive fluorescent analog, Birk and colleagues showed SS-31 binds cardiolipin with high affinity, and that the SS-31/cardiolipin complex inhibits the peroxidase activity cytochrome c acquires when bound to cardiolipin. In a rat renal ischemia model, pretreatment preserved cristae membranes and prevented mitochondrial swelling (PMID 23813215). Szeto's 2014 review framed SS-31 as a "cardiolipin-protective" compound that keeps cytochrome c acting as an electron carrier rather than a peroxidase (PMID 24117165).
2020: membrane electrostatics and protein partners. Mitchell and colleagues found that SS-31 partitions into the membrane interfacial region with an affinity tied to surface charge, does not destabilize lamellar bilayers, alters lipid packing, and modulates the surface electrostatics of model and mitochondrial membranes, including calcium distribution at the interface (PMID 32273339). Chavez and colleagues used chemical cross-linking mass spectrometry in mitochondria and found SS-31 interacting proteins that are all known cardiolipin binders, in oxidative phosphorylation and 2-oxoglutarate metabolism (PMID 32554501).
2025: the regulatory description. The FDA label names the pharmacologic class "mitochondrial cardiolipin binder" and states that the drug "localizes to the inner mitochondrial membrane and improves mitochondrial morphology and function". The label also reports that elamipretide is metabolized by sequential C-terminal degradation to a tripeptide (M1) and a dipeptide (M2) that have no pharmacological activity, all excreted in urine.
The practical point for a reader is that "SS-31 is an antioxidant" and "SS-31 binds cardiolipin" are both in the literature, from different decades, and the second is the account the field and the regulator now use.
What the animal work does and does not show. Several of the top-ranking pages cite aged-mouse data. In one such study, Campbell and colleagues compared young (5-month) and aged (26-month) female C57BL/6 mice over an 8-week study period and reported that SS-31 reversed the age-related decline in maximal mitochondrial ATP production (ATPmax) and oxidative phosphorylation coupling (P/O) measured by spectroscopy, and shifted glutathione redox status and protein S-glutathionylation in skeletal muscle (PMID 30597195). The same measurement, ATPmax, was also the primary endpoint of the MOTION trial in older adults (run 2015 to 2016, published 2021), where it rose immediately after a single administration, showed no difference from placebo at day 7, and was not accompanied by any effect on the trial's fatigue-resistance measure (PMID 34264994). That pattern, a clear mouse result beside a small and short-lived human signal, is typical of this compound's record.
The Clinical Record, Trial by Trial
A ClinicalTrials.gov search for elamipretide as an intervention returns 22 records, from phase 1 to phase 4, and the results are more mixed than most summaries say. The table lists the trials with published results; every figure is from the paper or the ClinicalTrials.gov record cited.
| Trial (registry) | Population and size | Primary endpoint | Result |
|---|---|---|---|
| EMBRACE STEMI (NCT01572909) | First anterior STEMI undergoing primary PCI; 300 enrolled | Infarct size by CK-MB area under the curve over 72 h | Not met: 5,785 vs 5,570 ng·h/mL, placebo vs elamipretide, not significant (PMID 26586786) |
| Single-administration HFrEF study (NCT02388464) | Ejection fraction 35% or less; 36 participants | Safety and tolerability | No serious adverse events; at the highest exposure, LV end-diastolic volume fell 18 mL and end-systolic volume 14 mL vs placebo at end of administration (PMID 29217757) |
| EVOLVE, renal artery stenosis (NCT01755858) | Atherosclerotic renal artery stenosis undergoing stenting; 6 elamipretide, 8 placebo | Renal function, oxygenation, blood flow | Pilot: stenotic kidney blood flow rose from 202 to 262 mL/min at 3 months in the elamipretide group only (PMID 28916603) |
| MMPOWER (NCT02367014) | Primary mitochondrial myopathy; 36 | 6-minute walk test (6MWT) after 5 days | Top exposure group walked 64.5 m further vs 20.4 m on placebo (p = 0.053); trend across the three exposure levels p = 0.014 (PMID 29500292) |
| MMPOWER-2 (NCT02805790) | Primary mitochondrial myopathy; 30, crossover | 6MWT | Not met: difference 19.8 m (95% CI -2.8 to 42.5; p = 0.0833); fatigue scores nominally favoured elamipretide (PMID 32096613) |
| PROGRESS-HF (NCT02788747) | Stable HFrEF; 71 | LV end-systolic volume by cardiac MRI at 4 weeks | Not met (p = 0.90 and 0.28 for the two arms vs placebo) (PMID 32068002) |
| MOTION (NCT02245620) | Older adults selected for poorly functioning skeletal muscle mitochondria; 41 enrolled | Maximal ATP synthesis rate (ATPmax) in hand muscle | ATPmax rose after a single administration (p = 0.055; percentage change p = 0.045); no difference at day 7 and no effect on fatigue resistance (PMID 34264994) |
| TAZPOWER part 1 (NCT03098797) | Barth syndrome; 12, crossover | 6MWT and BTHS Symptom Assessment fatigue | Neither met; week-12 6MWT 443.1 m on elamipretide vs 443.9 m on placebo (ClinicalTrials.gov results; PMID 33077895) |
| TAZPOWER part 2 (open-label) | 10 entered, 8 reached week 168 | Safety (extension) | 6MWT +95.9 m at week 36 (p = 0.024) and a cumulative +96.1 m at week 168 (p = 0.003), no placebo comparison (PMID 33077895, PMID 38602181) |
| MMPOWER-3 (NCT03323749) | Primary mitochondrial myopathy; 218 | 6MWT and PMMSA total fatigue at 24 weeks | Not met: 6MWT difference -3.2 m (95% CI -18.7 to 12.3; p = 0.69) (PMID 37268435) |
| ReCLAIM-2 (NCT03891875) | Dry AMD with geographic atrophy; 176 | Low-luminance visual acuity and geographic atrophy area | Not met; ellipsoid zone loss progressed 43% less (nominal p = 0.0034), a secondary measure (PMID 39605874) |
Barth syndrome: why one trial carries the approval
Barth syndrome is an X-linked disorder of tafazzin (TAZ), the enzyme that remodels cardiolipin, so affected mitochondria carry abnormal cardiolipin and a raised monolysocardiolipin to cardiolipin ratio (PMID 33077895, PMID 38602181). That makes it the indication where a cardiolipin-binding compound has the most direct rationale. The sponsor's announcement puts the US population at about 150 people.
TAZPOWER randomized 12 participants to 12 weeks of elamipretide or placebo, a 4-week washout, then 12 weeks on the other arm. In part 1 neither primary endpoint was met. Ten participants entered the open-label extension, eight reached week 168, and the extension reported improvements in 6MWT, fatigue scores, knee extensor strength, three-dimensional left ventricular volumes and the monolysocardiolipin to cardiolipin ratio (PMID 38602181). Those extension findings have no concurrent placebo group. A 2023 analysis used hierarchical clustering of the time-series data to look for responders (PMID 37041653).
Primary mitochondrial myopathy: a phase 3 miss and a genotype subgroup
MMPOWER-3 was the program's largest trial: 218 adults with genetically confirmed primary mitochondrial myopathy, 74% with mitochondrial DNA variants, randomized for 24 weeks. Both primary endpoints were missed, and the ClinicalTrials.gov record shows the study terminated because the double-blind part "did not meet the primary end points" (PMID 37268435). A post hoc analysis found that participants with nuclear DNA variants in mtDNA replisome genes (mostly POLG and TWNK) walked 25.2 m further against 2.0 m on placebo (p = 0.06), and that finding was used to design NuPower (PMID 39574155). NuPower (NCT05162768) enrolled 102 participants, was completed in December 2024, and had no results posted on ClinicalTrials.gov when this article was checked.
Heart, kidney and eye
The cardiac program produced one favourable signal in a single-administration study and two misses in larger trials (EMBRACE STEMI and PROGRESS-HF). The ophthalmology program missed its phase 2 primary endpoints in ReCLAIM-2 but moved the ellipsoid zone measure, a marker of photoreceptor integrity, into the primary endpoint of the phase 3 ReNEW trial (NCT06373731, 313 enrolled, active and not recruiting). A small pilot in renal artery stenosis reported higher renal blood flow at three months. Each of these is a population-specific endpoint result, and none is a statement about what the compound does outside that trial.
For reading these numbers, see why two trials of one compound can report different figures: an open-label change from baseline and a placebo-controlled difference answer different questions.
The FDA Decision: How the 2025 Approval Was Reached
The regulatory history is short on paper and contested in substance. Every date below is from FDA documents for NDA 215244.
| Date | Event | Source |
|---|---|---|
| 10 October 2024 | Cardiovascular and Renal Drugs Advisory Committee votes 10 yes, 6 no, 0 abstain on whether elamipretide is effective for Barth syndrome | FDA summary minutes |
| 15 May 2025 | FDA issues a Complete Response letter, citing no substantial evidence of effectiveness and a manufacturing facility issue; the letter names knee extensor strength as a possible intermediate endpoint | FDA integrated review |
| 15 August 2025 | Sponsor resubmits; the facility is reclassified as Voluntary Action Indicated | FDA integrated review |
| 19 September 2025 | Accelerated approval granted, with priority review and a rare pediatric disease priority review voucher | FDA press announcement |
What was approved. The indication, in the label's words, is "to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg", and continued approval "may be contingent upon verification and description of clinical benefit in a confirmatory trial". Accelerated approval rests on an endpoint the FDA judges "reasonably likely" to predict benefit, here the strength of the knee extensors, measured by handheld dynamometry.
The numbers behind it. The label's Table 3 reports a pre-trial median knee extensor strength of 124 newtons. During the randomized part, the median change was -5 N on placebo and +4 N on elamipretide. In the open-label extension, median changes from the original baseline were +34 N at week 12, +68 N at week 24 and +63 N at week 168, in 8 to 10 participants. The FDA label states plainly that the drug "was not superior to placebo" on the randomized trial's primary endpoints.
The disagreement. The integrated review records that the clinical and statistical reviewers and the cross-discipline team leader concluded the strength data were "not adequate for traditional or accelerated approval" and recommended a second Complete Response. The director of the Office of Cardiology, Hematology, Endocrinology and Nephrology, as signatory authority, concluded that the extension's strength increases were large and sustained enough to support accelerated approval for "this very rare disease with high unmet need", while accepting "a somewhat greater risk ... of false positive conclusions". The same review lists postmarketing requirements: a confirmatory trial, two carcinogenicity studies and a drug interaction study.
The confirmatory trial. 4TAZPower (NCT07531251) is a phase 3b/4, randomized, quadruple-masked, placebo-controlled trial in genetically confirmed Barth syndrome over 72 weeks, planned at 48 participants and recruiting as of its November 2026 registry update.
Canada. A search of Health Canada's Drug Product Database for the ingredient "elamipretide" returned no product on 14 November 2026, so no elamipretide drug is marketed in Canada. The MMPOWER-3 author list includes investigators from Vancouver General Hospital and McMaster University (PMID 37268435). For how research reagents are treated in Canada, see Are Peptides Legal in Canada?.
Research-Grade SS-31 Versus the Approved Drug Product
A research vial and the approved elamipretide product share an active molecule and almost nothing else that a trial depends on.
| Approved elamipretide product (FDA label) | Research-grade SS-31 vial | |
|---|---|---|
| Salt form | Trihydrochloride, 749.2 g/mol | Varies by supplier; commonly an acetate or trifluoroacetate salt from synthesis, and not always stated |
| Physical form | Refrigerated aqueous solution with benzyl alcohol as preservative | Lyophilized powder |
| Specification and control | NDA-approved specifications, inspected manufacturing facility | Supplier's release specification and a laboratory certificate of the lot |
| Evidence that applies | The trials and the label | The certificate for that lot |
| Status | Prescription medicine for one indication in the US | Laboratory reagent, not for human use |
The trial results above were produced with the sponsor's drug product, made to an approved specification under inspected manufacturing. They say nothing about the content, purity, salt form or stability of a research vial, and a vial's certificate says nothing about any clinical effect. The two kinds of evidence answer different questions and should be kept apart in any protocol or purchasing record.
Verifying SS-31: Why Mass Alone Is Not Enough
SS-31 is only four residues long, and that small size is what makes its identity harder to prove than it looks. Three specific problems follow from its structure.
Problem 1: a sequence isomer with the same exact mass
[Dmt1]DALDA, H-Dmt-D-Arg-Phe-Lys-NH2, contains exactly the same residues and C-terminal amide as SS-31 in a different order. PubChem lists it (CID 9809562) with the same formula, C32H49N9O5, and the same monoisotopic mass, 639.3857 Da. A full-scan mass spectrum showing the expected mass therefore cannot distinguish SS-31 from a well-characterized mu opioid agonist (PMID 14534366). Sequence-specific fragments can: by our calculation, the C-terminal y1 ion of SS-31 is phenylalaninamide (about m/z 165.1), while that of [Dmt1]DALDA is lysinamide (about m/z 146.1). Retention time against an authentic SS-31 reference standard adds a second, independent check.
Problem 2: stereoisomers with the same mass and the same fragments
The D-configuration of arginine is part of the defined molecule. An all-L version, or a product epimerized at any residue during synthesis, has the same formula, the same mass and the same fragment ions. Ordinary MS and MS/MS cannot reliably tell them apart. What can:
- Chromatographic resolution against a reference. Peptide diastereomers can often be separated on reversed-phase or chiral columns, so co-elution with an authentic standard is informative only if the method has been shown to resolve the alternative isomer.
- Chiral amino acid analysis. Hydrolysing the peptide and derivatizing the amino acids with Marfey's reagent lets D- and L-arginine be separated and measured (PMID 15503232). Acid hydrolysis itself creates some of the wrong enantiomer, so careful methods account for hydrolysis-induced racemization (PMID 20564678).
The general framework for what each identity method proves is set out in our guide to peptide identity testing, and how to verify a peptide in Canada covers sending a vial to an independent laboratory, several of which are listed in our testing laboratories directory.
Problem 3: salt form and net peptide content
Because SS-31 carries three basic groups, each molecule pairs with up to three counter-ions, and the counter-ion's mass is a large share of a four-residue peptide. Using PubChem's 639.8 g/mol for the free base:
| Salt (three counter-ions) | Formula weight | Peptide share of the salt mass |
|---|---|---|
| Trihydrochloride (the approved drug substance) | 749.2 g/mol (FDA label) | about 85% |
| Triacetate | about 820 g/mol (calculated) | about 78% |
| Tri-trifluoroacetate | about 982 g/mol (calculated) | about 65% |
The calculated rows assume exactly three counter-ions; real lots also hold water and may differ from ideal stoichiometry. This is why chromatographic purity and net peptide content are separate measurements: purity is a ratio of peaks and is silent about how much peptide is in the vial. The effect is larger for a short peptide than a long one, a point developed in our article on chain length and counter-ions.
The degradation products to look for
The FDA label's description of metabolism, sequential loss from the C-terminus, points to the truncation products a purity method should be able to resolve: peptides missing the C-terminal residue or the last two residues. Deamidation of the C-terminal amide to a free acid changes the mass by about 1 Da and is another impurity a method should separate.
Volta's Certificate for the SS-31 10 mg Vial
Volta's SS-31 10mg is the only SS-31 size in the catalogue. Its release specification is >99% purity by HPLC, which is a specification and not a measurement. The certificate below is a measurement of one lot, and it applies only to that lot of the 10 mg vial.
| Field | Reported value |
|---|---|
| Laboratory and report | SideChain Analytics, COA-2026-SC-02806, reported 27 September 2026 |
| Lot | VPS310100 |
| Chromatographic purity | 99.6% (principal-component peak area) |
| Net peptide content | 11.26 mg against a 10 mg label claim (112.6%) |
| Identity | Confirmed against a reference standard by HPLC-MS/MS, MRM transition 320.7 › 120.1 |
The transition is readable from the chemistry. 320.7 is the doubly protonated molecule, [M+2H]2+, calculated from the monoisotopic mass as (639.386 + 2 × 1.007) / 2 = 320.70. 120.1 corresponds to the phenylalanine immonium ion (C8H10N+, 120.08). Identity was confirmed against a reference standard, as the report states. The full report, with the laboratory's own verification link, is in our certificate archive, and the compound overview is at /peptides/ss-31.
Frequently Asked Questions
What is SS-31?
SS-31 is elamipretide, a synthetic tetrapeptide with the sequence D-Arg-Dmt-Lys-Phe-NH2, where Dmt is 2',6'-dimethyl-L-tyrosine. PubChem lists the free base as C32H49N9O5, 639.8 g/mol, CAS 736992-21-5. In laboratory studies it concentrates at the inner mitochondrial membrane and interacts with cardiolipin.
Is SS-31 the same as elamipretide, Bendavia and MTP-131?
Yes. SS-31 is the Szeto-Schiller series name, MTP-131 and Bendavia were development names used by Stealth BioTherapeutics, and elamipretide is the international nonproprietary name. PubChem lists all of them as synonyms of CID 11764719.
Is SS-31 FDA approved?
An elamipretide product received FDA accelerated approval on 19 September 2025 for one indication, which the label states as "to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg". The approval is based on knee extensor strength as an intermediate endpoint and depends on a confirmatory trial. It is not approved for any other condition, and research-grade SS-31 is not an FDA-approved drug.
Is elamipretide approved in Canada?
No elamipretide product appears in Health Canada's Drug Product Database, which returned no match for the ingredient when searched on 14 November 2026.
Why do some sources say SS-31 was discontinued?
The development program was not discontinued, but parts of it stopped. MMPOWER-3 was terminated after its double-blind part missed the primary endpoints, and the FDA issued a Complete Response letter in May 2025 before approving a resubmission in September 2025. A phase 3 eye trial and a confirmatory Barth syndrome trial are registered as active or recruiting.
How does elamipretide work?
The FDA describes it as a mitochondrial cardiolipin binder that localizes to the inner mitochondrial membrane. Laboratory studies show it binds cardiolipin, inhibits the peroxidase activity cytochrome c acquires when bound to cardiolipin, preserves cristae structure in ischemia models, and changes the surface charge of mitochondrial membranes.
Is SS-31 an antioxidant?
It was first described as one: a 2004 study attributed its reduction of mitochondrial reactive oxygen species to the Dmt residue. Later work explains the effect mainly through cardiolipin binding, and the FDA's class name is cardiolipin binder, not antioxidant.
Did the MMPOWER-3 trial fail?
MMPOWER-3 did not meet either primary endpoint. In 218 adults with primary mitochondrial myopathy, the 24-week difference in 6-minute walk distance was -3.2 m (p = 0.69). A post hoc subgroup with mtDNA replisome variants showed a trend that led to the NuPower trial, whose results were not posted at the time of writing.
Is a research-grade SS-31 vial the same as the approved drug?
No. The approved product is a trihydrochloride salt in a preserved aqueous solution, made to an approved specification under inspected manufacturing. A research vial is lyophilized powder whose salt form varies by supplier and whose quality is described only by its own lot certificate. Trial results do not describe a research vial.
How can a laboratory confirm SS-31's identity?
Mass alone is not sufficient, because [Dmt1]DALDA has the same formula and exact mass and an L-Arg diastereomer has the same mass and fragments. Identity needs sequence-specific MS/MS fragments, retention against an authentic reference standard with a method shown to resolve isomers, and chiral amino acid analysis where the D-Arg configuration must be proven.
How is SS-31 different from MOTS-c?
They are unrelated molecules that are often discussed together because both concern mitochondria. SS-31 is a synthetic four-residue peptide containing D-Arg and Dmt that acts at the inner mitochondrial membrane through cardiolipin. MOTS-c is a 16-amino-acid peptide encoded by a short open reading frame in the mitochondrial 12S rRNA gene, which in the original mouse and cell work was reported to inhibit folate metabolism and de novo purine synthesis, leading to AMPK activation (PMID 25738459). The MOTS-c overview covers it separately.
What is the molecular weight of SS-31?
The free base is 639.8 g/mol with a monoisotopic mass of 639.3857 Da. The trihydrochloride used in the approved product is 749.2 g/mol, and acetate or trifluoroacetate salts weigh more, which is why net peptide content is measured separately from purity.
Sources
- PubChem, Elamipretide, CID 11764719: formula, weight, monoisotopic mass, IUPAC name, synonyms. https://pubchem.ncbi.nlm.nih.gov/compound/11764719 (retrieved 14 November 2026)
- PubChem, [Dmt1]DALDA, CID 9809562. https://pubchem.ncbi.nlm.nih.gov/compound/9809562 (retrieved 14 November 2026)
- US FDA. FDA grants accelerated approval to first treatment for Barth syndrome, 19 September 2025. https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-first-treatment-barth-syndrome (retrieved 14 November 2026)
- US FDA. Approved product label, NDA 215244 (elamipretide), sections 1, 11, 12 and 14. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215244s000lbl.pdf (retrieved 14 November 2026)
- US FDA. Integrated Review, NDA 215244Orig1s000. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/215244Orig1s000IntegratedR.pdf (retrieved 14 November 2026)
- US FDA. Summary minutes, Cardiovascular and Renal Drugs Advisory Committee, 10 October 2024. https://www.fda.gov/media/187179/download (retrieved 14 November 2026)
- Stealth BioTherapeutics. Press release announcing FDA accelerated approval of elamipretide HCl for Barth syndrome, 19 September 2025, distributed via BioSpace (retrieved 14 November 2026)
- Health Canada Drug Product Database, active ingredient search "elamipretide". https://health-products.canada.ca/api/drug/activeingredient/?lang=en&type=json&ingredientname=elamipretide (retrieved 14 November 2026)
- ClinicalTrials.gov records: NCT01572909, NCT02388464, NCT01755858, NCT02367014, NCT02805790, NCT02788747, NCT02245620, NCT03098797, NCT03323749, NCT03891875, NCT05162768, NCT06373731, NCT07531251. https://clinicaltrials.gov (retrieved 14 November 2026)
- Zhao K, Zhao GM, Wu D, et al. Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. J Biol Chem. 2004;279(33):34682-90. PMID 15178689
- Szeto HH. Cell-permeable, mitochondrial-targeted, peptide antioxidants. AAPS J. 2006;8(2):E277-83. PMID 16796378
- Birk AV, Liu S, Soong Y, et al. The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. J Am Soc Nephrol. 2013;24(8):1250-61. PMID 23813215
- Szeto HH, Schiller PW. Novel therapies targeting inner mitochondrial membrane--from discovery to clinical development. Pharm Res. 2011;28(11):2669-79. PMID 21638136
- Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. Br J Pharmacol. 2014;171(8):2029-50. PMID 24117165
- Mitchell W, Ng EA, Tamucci JD, et al. The mitochondria-targeted peptide SS-31 binds lipid bilayers and modulates surface electrostatics as a key component of its mechanism of action. J Biol Chem. 2020;295(21):7452-7469. PMID 32273339
- Chavez JD, Tang X, Campbell MD, et al. Mitochondrial protein interaction landscape of SS-31. Proc Natl Acad Sci U S A. 2020;117(26):15363-15373. PMID 32554501
- Zhu Y, Luo M, Bai X, et al. SS-31, a Mitochondria-Targeting Peptide, Ameliorates Kidney Disease. Oxid Med Cell Longev. 2022;2022:1295509. PMID 35707274
- Zhao GM, Qian X, Schiller PW, Szeto HH. Comparison of [Dmt1]DALDA and DAMGO in binding and G protein activation at mu, delta, and kappa opioid receptors. J Pharmacol Exp Ther. 2003;307(3):947-54. PMID 14534366
- Berezowska I, Chung NN, Lemieux C, et al. Highly potent fluorescent analogues of the opioid peptide [Dmt1]DALDA. Peptides. 2003;24(8):1195-200. PMID 14612191
- Gibson CM, Giugliano RP, Kloner RA, et al. EMBRACE STEMI study: a Phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary intervention. Eur Heart J. 2016;37(16):1296-303. PMID 26586786
- Daubert MA, Yow E, Dunn G, et al. Novel Mitochondria-Targeting Peptide in Heart Failure Treatment: A Randomized, Placebo-Controlled Trial of Elamipretide. Circ Heart Fail. 2017;10(12). PMID 29217757
- Saad A, Herrmann SMS, Eirin A, et al. Phase 2a Clinical Trial of Mitochondrial Protection (Elamipretide) During Stent Revascularization in Patients With Atherosclerotic Renal Artery Stenosis. Circ Cardiovasc Interv. 2017;10(9). PMID 28916603
- Karaa A, Haas R, Goldstein A, et al. Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy. Neurology. 2018;90(14):e1212-e1221. PMID 29500292
- Karaa A, Haas R, Goldstein A, et al. A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy. J Cachexia Sarcopenia Muscle. 2020;11(4):909-918. PMID 32096613
- Butler J, Khan MS, Anker SD, et al. Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial. J Card Fail. 2020;26(5):429-437. PMID 32068002
- Roshanravan B, Liu SZ, Ali AS, et al. In vivo mitochondrial ATP production is improved in older adult skeletal muscle after a single dose of elamipretide in a randomized trial. PLoS One. 2021;16(7):e0253849. PMID 34264994
- Reid Thompson W, Hornby B, Manuel R, et al. A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism. Genet Med. 2021;23(3):471-478. PMID 33077895
- Van den Eynde J, Chinni B, Vernon H, et al. Identifying responders to elamipretide in Barth syndrome: Hierarchical clustering for time series data. Orphanet J Rare Dis. 2023;18(1):76. PMID 37041653
- Karaa A, Bertini E, Carelli V, et al. Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial. Neurology. 2023;101(3):e238-e252. PMID 37268435
- Thompson WR, Manuel R, Abbruscato A, et al. Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER. Genet Med. 2024;26(7):101138. PMID 38602181
- Karaa A, Bertini E, Carelli V, et al. Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER-3 trial. Orphanet J Rare Dis. 2024;19(1):431. PMID 39574155
- Ehlers JP, Hu A, Boyer D, et al. ReCLAIM-2: A Randomized Phase II Clinical Trial Evaluating Elamipretide in Age-related Macular Degeneration, Geographic Atrophy Growth, Visual Function, and Ellipsoid Zone Preservation. Ophthalmol Sci. 2025;5(1):100628. PMID 39605874
- Campbell MD, Duan J, Samuelson AT, et al. Improving mitochondrial function with SS-31 reverses age-related redox stress and improves exercise tolerance in aged mice. Free Radic Biol Med. 2019;134:268-281. PMID 30597195
- Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-54. PMID 25738459
- Bhushan R, Brückner H. Marfey's reagent for chiral amino acid analysis: a review. Amino Acids. 2004;27(3-4):231-47. PMID 15503232
- Miyamoto T, Sekine M, Ogawa T, et al. Generation of enantiomeric amino acids during acid hydrolysis of peptides detected by the liquid chromatography/tandem mass spectroscopy. Chem Biodivers. 2010;7(6):1644-50. PMID 20564678
- SideChain Analytics, certificate COA-2026-SC-02806, SS-31 10mg, lot VPS310100, reported 27 September 2026. https://www.sidechainanalytics.com/verify/U_COhaf9q6E117-i-1CqHA

